S Jeson Sangaralingham Selected Research

S Jeson Sangaralingham Research Topics

Disease

19	Heart Failure 12/2021 - 12/2011
10	Fibrosis (Cirrhosis) 10/2021 - 02/2011
9	Hypertension (High Blood Pressure) 12/2021 - 12/2010
3	Metabolic Diseases (Metabolic Disease) 01/2018 - 01/2015
3	Chronic Renal Insufficiency 12/2015 - 01/2015
3	Cardiomegaly (Heart Hypertrophy) 12/2007 - 03/2003
2	Inflammation (Inflammations) 10/2021 - 05/2017
2	Systolic Heart Failure 04/2021 - 01/2020
2	Myocardial Infarction 01/2021 - 08/2013
2	Hypotension (Low Blood Pressure) 10/2019 - 01/2018
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 06/2015
2	Obesity 12/2015 - 01/2015
2	Abdominal Obesity 12/2015 - 01/2015
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2015 - 12/2007
1	Hypertrophy 12/2021
1	Neoplasms (Cancer) 10/2021
1	Atrophy 10/2021
1	Acute Kidney Injury (Acute Renal Failure) 04/2021
1	Renal Insufficiency (Renal Failure) 04/2021
1	Dysbiosis 01/2020
1	Ischemia 10/2019
1	Disease Progression 01/2019
1	Type 2 Diabetes Mellitus (MODY) 12/2015
1	Hypoxia (Hypoxemia) 03/2015
1	Atrial Fibrillation 01/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2015
1	Infarction (Infarctions) 08/2013
1	Atrial Remodeling 01/2013
1	Proteinuria 01/2012
1	Left Ventricular Dysfunction 01/2012
1	Stroke (Strokes) 12/2011

Drug/Important Bio-Agent (IBA)

11	Atrial Natriuretic Factor (ANF)IBA 12/2021 - 12/2007
8	AldosteroneIBA 01/2018 - 12/2010
7	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA 01/2021 - 02/2011
7	Natriuretic PeptidesIBA 10/2019 - 01/2013
6	Biomarkers (Surrogate Marker)IBA 10/2019 - 11/2011
5	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 12/2011
3	sacubitril and valsartan sodium hydrate drug combinationIBA 04/2021 - 01/2018
3	atrial natriuretic factor receptor AIBA 01/2020 - 01/2019
3	Hormones (Hormone)IBA 01/2020 - 03/2015
2	Angiotensin Receptor AntagonistsIBA 04/2021 - 01/2020
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 04/2021 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2019
2	CRRL269IBA 10/2019 - 01/2018
2	Peptides (Polypeptides)IBA 01/2019 - 01/2013
2	Proteins (Proteins, Gene)FDA Link 05/2017 - 01/2013
2	CollagenIBA 02/2016 - 01/2012
2	CytokinesIBA 02/2016 - 03/2015
2	Guanylate Cyclase (Guanylyl Cyclase)IBA 10/2014 - 01/2014
2	Angiotensin IIIBA 01/2014 - 12/2010
2	Messenger RNA (mRNA)IBA 01/2013 - 03/2003
2	SaltsIBA 12/2007 - 07/2007
2	Estrogens (Estrogen)FDA Link 12/2007 - 07/2007
1	CreatinineIBA 04/2021
1	sacubitrilIBA 01/2020
1	Biological ProductsIBA 01/2020
1	SphingolipidsIBA 01/2020
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2018
1	cenderitideIBA 01/2018
1	Antihypertensive Agents (Antihypertensives)IBA 01/2018
1	Cyclic GMPIBA 01/2018
1	Tissue Inhibitor of MetalloproteinasesIBA 02/2016
1	Transforming Growth Factor beta (TGF-beta)IBA 02/2016
1	EnzymesIBA 02/2016
1	Matrix Metalloproteinases (MMPs)IBA 02/2016
1	LipidsIBA 12/2015
1	crisamicin CIBA 03/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2015
1	Pro-BNP1-108IBA 01/2015
1	Triglycerides (Triacylglycerol)IBA 01/2015
1	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2014
1	Soluble Guanylyl CyclaseIBA 01/2014
1	ReninIBA 05/2013
1	AngiotensinsIBA 05/2013
1	Natriuretic AgentsIBA 01/2013
1	FurinIBA 01/2013
1	salicylhydroxamic acid (SHAM)IBA 01/2012
1	pro-brain natriuretic peptide (1-76)IBA 12/2011

Therapy/Procedure

7	Therapeutics 01/2020 - 01/2014
3	Nephrectomy 10/2021 - 01/2012
1	Heart-Assist Devices 10/2014
1	Subcutaneous Infusions 01/2012